Qualigen Therapeutics

$3.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.30%) Today
+$0.09 (+2.69%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell QLGN and other stocks, options, and ETFs commission-free!

About QLGN

Qualigen Therapeutics, Inc. Common Stock, also called Qualigen Therapeutics, is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA. The listed name for QLGN is Qualigen Therapeutics, Inc. Common Stock.

CEO
Michael S. Poirier
Employees
5
Headquarters
Los Angeles, California
Founded
—
Market Cap
89.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.37M
High Today
$3.43
Low Today
$3.26
Open Price
$3.42
Volume
735.84K
52 Week High
$21.25
52 Week Low
$2.87

Collections

QLGN Earnings

-$2.12
-$1.41
-$0.71
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Feb 11, After Hours

You May Also Like

JAMF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure